K145 (K-145) is a novel, potent and selective SphK2 (sphingosine kinase-2) inhibitor with anticancer effects.

K145 is a novel and selective SphK2 (sphingosine kinase-2) inhibitor (IC50 = 4.30 μM) with antitumor activity.

Defensamide (formerly known as MHP and methyl caprooyl tyrosinate) is a novel and potent activator of sphingosine kinase (SPHK1), and significantly stimulates CAMP mRNA and protein production in KC.

SKI-178 is a sphingosine kinase 1 (SphK1) inhibitor (IC50 = 0.1-1.8 μM) which is a novel therapeutic agent for the treatment of AML, including multidrug-resistant/recurrent AML subtypes.

MP-A08 is a novel and potent sphingosine kinase inhibitor.

K6PC-5 is a novel and potent sphingosine kinase 1 (SphK1) activator with potential usefulness for skin diseases.